MT-TP and homozygous familial hypercholesterolemia: Another agent that has demonstrated its efficacy on HoFH patients is lomipatide, the target of which is the inhibition of the microsomal triglyceride transport protein (MTTP) in the endoplasmic reticulum of hepatic and intestinal cells, causing a decrease in the secretion of very-low-density lipoprotein (VLDL) cholesterol and chylomicrons into the circulatory system.